Inside The Gene Therapy For Coronary Artery Disease With XyloCor Therapeutics' Albert Gianchetti
Source: Cell & Gene
XyloCor Therapeutics' EXACT clinical trial is a Phase 1/2 multicenter, open-label, single arm, dose escalation trial for coronary artery disease — the most common type of heart disease — with gene therapy at its center.
This website uses cookies to ensure you get the best experience on our website. Learn more